Clinical trial · Interventional
Phase 1 Study of Mesothelin-ADC
A Phase 1 Study of the Safety and Tolerability of BMS 986148 in Subjects With Advanced and/or Metastatic Solid Tumors
NCT02884726CI-TRIAL-00044145completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the safety and tolerability of Mesothelin-ADC in subjects with advanced and/or metastatic solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986148 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BMS-986148 intravenous infusion
- interventionNames
- Drug: BMS-986148
Primary outcomes (4)
- measure
- Incidence of AEs (Adverse Events)
- timeFrame
- Day 1 to 30 days after the last dose of BMS-986148
- description
- AEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
- measure
- Incidence of SAEs (Serious Adverse Events)
- timeFrame
- Day 1 to 30 days after the last dose of BMS-986148
- description
- SAEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Must have histological confirmation of advanced and/or metastatic solid tumors which are expected to express mesothelin * Must have received and either progressed or been intolerant to the standard treatment regimen in the advanced or metastatic setting, if such a therapy exists * Must have measurable tumor per Response Evaluation Criteria in Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 Exclusion Criteria: * Cancer metastases in the brain * Uncontrolled or significant cardiovascular disease * Moderate eye disorders * Moderate peripheral neuropathy * Known past or active hepatitis B or C infection Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.